Skip to main content

Table 2 Baseline laboratory investigations of type 2 diabetes mellitus patients divided according to the cardiovascular death

From: Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long‐term follow‐up study

Variable

Non-survivors (n = 16)

Survivors (n = 117)

P-value

Basic

 HbA1c, %

6.7 (6.2–8.5)

6.4 (6.1–7.1)

0.25

 Fasting glucose, mmol/l

5.0 (4.2–6.5)

6.0 (5.3–7.4)

0.06

 Creatinine, µmol/l

82.0 (77.0–113.5)

81.0 (65.0–96.0)

0.17

 Total cholesterol, mmol/l

3.4 (3.3–4.4)

4.3 (3.6–5.0)

0.03

 LDL-cholesterol, mmol/l

1.7 (1.4–2.4)

2.4 (1.9–3.0)

0.01

 HDL-cholesterol, mmol/l

1.2 (1.0–1.5)

1.3 (1.1–1.6)

0.30

 Triglycerides, mmol/l

1.0 (0.9–1.6)

1.3 (1.0–1.8)

0.22

 High-sensitivity C-reactive protein, mg/l

3.3 (1.9–6.0)

1.9 (1.0–3.4)

0.04

Coagulation parameters

 Fibrinogen, g/l

3.2 (2.8–3.5)

3.0 (2.6–3.5)

0.32

 Peak thrombin, nM

253.5 (212.0–289.5)

228.0 (201.0–268.0)

0.17

 Plasminogen activity, %

105.5 (88.5–115.5)

105.0 (98.0–117.0)

0.48

 tPA antigen, ng/ml

11.8 (9.3–15.6)

11.2 (10.0–13.2)

0.49

 PAI-1 antigen, ng/ml

32.1 (29.5–37.1)

32.1 (29.5–37.1)

0.88

 α2-antiplasmin activity, %

115.0 (101.0–121.0)

115.0 (101.0–121.0)

0.16

 TAFI activity, %

97.5 (89.0–106.0)

97.5 (89.0–106.0)

0.72

 Thrombomodulin antigen, ng/ml

3.1 (2.3–3.6)

3.01 (2.3–3.6)

0.91

Fibrin clot properties

 Lag phase, s

42.5 (40.0–44.5)

43.0 (40.0–46.0)

0.67

 ∆Abs, 405 nm

0.825 (0.800–0.860)

0.810 (0.770–0.850)

0.26

 Ks, × 10–9 cm2

7.0 (6.2–7.3)

7.1 (6.6–7.7)

0.13

 Compaction, %

44.0 (39.5–46.0)

44.0 (40.0–49.0)

0.47

 CLT, min

88.0 (79.0–104.5)

95.0 (82.0–105.0)

0.45

 t50%, min

10.15 (9.60–10.95)

9.8 (9.0–10.4)

0.06

 D-Dmax, mg/l

4.18 (3.77–4.48)

3.85 (3.60–4.09)

0.01

 D-Drate, mg/l/min

0.069 (0.064–0.071)

0.070 (0.068–0.073)

0.02

  1. Data are presented as the median (interquartile range) and compared using Mann–Whitney test
  2. HbA1c glycated hemoglobin, LDL low-density lipoprotein, HDL high-density lipoprotein, tPA tissue plasminogen activator, PAI plasminogen activator inhibitor 1, TAFI thrombin-activatable fibrinolysis inhibitor, Ks permeability coefficient, ∆Abs maximum absorbance at plateau, t50% the time required for a 50% decrease in clot turbidity, CLT clot lysis time, D-Dmax maximum D-dimer concentrations, D-Drate maximum rates of increase in D-dimer levels